1. Home
  2. SKYT vs RGNX Comparison

SKYT vs RGNX Comparison

Compare SKYT & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYT
  • RGNX
  • Stock Information
  • Founded
  • SKYT 1991
  • RGNX 2008
  • Country
  • SKYT United States
  • RGNX United States
  • Employees
  • SKYT N/A
  • RGNX N/A
  • Industry
  • SKYT Semiconductors
  • RGNX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SKYT Technology
  • RGNX Health Care
  • Exchange
  • SKYT Nasdaq
  • RGNX Nasdaq
  • Market Cap
  • SKYT 578.1M
  • RGNX 661.2M
  • IPO Year
  • SKYT 2021
  • RGNX 2015
  • Fundamental
  • Price
  • SKYT $14.59
  • RGNX $13.35
  • Analyst Decision
  • SKYT Strong Buy
  • RGNX Strong Buy
  • Analyst Count
  • SKYT 5
  • RGNX 7
  • Target Price
  • SKYT $19.40
  • RGNX $30.29
  • AVG Volume (30 Days)
  • SKYT 2.5M
  • RGNX 550.7K
  • Earning Date
  • SKYT 11-05-2025
  • RGNX 11-06-2025
  • Dividend Yield
  • SKYT N/A
  • RGNX N/A
  • EPS Growth
  • SKYT N/A
  • RGNX N/A
  • EPS
  • SKYT 2.62
  • RGNX N/A
  • Revenue
  • SKYT $346,587,000.00
  • RGNX $161,318,000.00
  • Revenue This Year
  • SKYT $24.43
  • RGNX $198.02
  • Revenue Next Year
  • SKYT $44.21
  • RGNX $2.67
  • P/E Ratio
  • SKYT $5.66
  • RGNX N/A
  • Revenue Growth
  • SKYT 0.19
  • RGNX 91.30
  • 52 Week Low
  • SKYT $5.67
  • RGNX $5.04
  • 52 Week High
  • SKYT $24.23
  • RGNX $13.93
  • Technical
  • Relative Strength Index (RSI)
  • SKYT 43.46
  • RGNX 63.58
  • Support Level
  • SKYT $13.56
  • RGNX $10.76
  • Resistance Level
  • SKYT $14.91
  • RGNX $12.05
  • Average True Range (ATR)
  • SKYT 2.09
  • RGNX 0.80
  • MACD
  • SKYT -0.46
  • RGNX 0.16
  • Stochastic Oscillator
  • SKYT 15.70
  • RGNX 80.65

About SKYT SkyWater Technology Inc.

SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Share on Social Networks: